CA2530117C - Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a plga matrix - Google Patents
Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a plga matrix Download PDFInfo
- Publication number
- CA2530117C CA2530117C CA2530117A CA2530117A CA2530117C CA 2530117 C CA2530117 C CA 2530117C CA 2530117 A CA2530117 A CA 2530117A CA 2530117 A CA2530117 A CA 2530117A CA 2530117 C CA2530117 C CA 2530117C
- Authority
- CA
- Canada
- Prior art keywords
- plga
- ethanol
- weight
- plasticized
- stage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 178
- 239000007943 implant Substances 0.000 title claims abstract description 37
- 238000007920 subcutaneous administration Methods 0.000 title claims abstract description 37
- 239000004014 plasticizer Substances 0.000 title abstract description 10
- 239000011159 matrix material Substances 0.000 title abstract description 5
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 26
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 26
- 238000001125 extrusion Methods 0.000 claims abstract description 13
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract 25
- 239000000203 mixture Substances 0.000 claims description 19
- 235000012438 extruded product Nutrition 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 9
- 238000000227 grinding Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000009835 boiling Methods 0.000 abstract description 2
- 229920000642 polymer Polymers 0.000 description 39
- 238000002360 preparation method Methods 0.000 description 24
- 102000002265 Human Growth Hormone Human genes 0.000 description 9
- 108010000521 Human Growth Hormone Proteins 0.000 description 9
- 239000000854 Human Growth Hormone Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 229960004532 somatropin Drugs 0.000 description 6
- 238000001542 size-exclusion chromatography Methods 0.000 description 5
- 238000004811 liquid chromatography Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/141—Plasticizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2003A001302 | 2003-06-26 | ||
| IT001302A ITMI20031302A1 (it) | 2003-06-26 | 2003-06-26 | Uso di etanolo come plasticizzante per preparare impianti sottocutanei contenenti principi attivi termolabili dispersi in una matrice di plga. |
| PCT/EP2004/051226 WO2005000277A1 (en) | 2003-06-26 | 2004-06-24 | Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a plga matrix |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2530117A1 CA2530117A1 (en) | 2005-01-06 |
| CA2530117C true CA2530117C (en) | 2012-01-10 |
Family
ID=30131301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2530117A Expired - Fee Related CA2530117C (en) | 2003-06-26 | 2004-06-24 | Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a plga matrix |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8206621B2 (enExample) |
| EP (1) | EP1638534B1 (enExample) |
| JP (1) | JP2009513165A (enExample) |
| KR (1) | KR101143771B1 (enExample) |
| CN (1) | CN100509060C (enExample) |
| AT (1) | ATE398447T1 (enExample) |
| AU (1) | AU2004251456B2 (enExample) |
| BR (1) | BRPI0411759A (enExample) |
| CA (1) | CA2530117C (enExample) |
| CY (1) | CY1108346T1 (enExample) |
| DE (1) | DE602004014496D1 (enExample) |
| ES (1) | ES2308195T3 (enExample) |
| IT (1) | ITMI20031302A1 (enExample) |
| MX (1) | MXPA05013697A (enExample) |
| PL (1) | PL1638534T3 (enExample) |
| PT (1) | PT1638534E (enExample) |
| WO (1) | WO2005000277A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7666445B2 (en) | 2000-10-20 | 2010-02-23 | The Trustees Of The University Of Pennsylvania | Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use |
| US8329203B2 (en) | 2004-01-12 | 2012-12-11 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| US8541028B2 (en) | 2004-08-04 | 2013-09-24 | Evonik Corporation | Methods for manufacturing delivery devices and devices thereof |
| EP1909689A4 (en) * | 2005-07-18 | 2011-11-16 | Univ Pennsylvania | PHARMACEUTICAL IMPLANTS AND METHOD OF USE THEREOF |
| ITMI20061539A1 (it) * | 2006-08-02 | 2008-02-03 | Mediolanum Pharmaceuticals Ltd | Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo |
| DE602007008125D1 (de) | 2006-10-31 | 2010-09-09 | Surmodics Pharmaceuticals Inc | Kugelförmige polymer-teilchen |
| ES2718612T3 (es) | 2007-12-20 | 2019-07-03 | Evonik Corp | Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual |
| US9498431B2 (en) * | 2008-12-10 | 2016-11-22 | Jianjian Xu | Controlled releasing composition |
| CA2804035A1 (en) * | 2010-06-30 | 2012-01-05 | Evonik Degussa Corporation | Implant processing methods for thermally labile and other bioactive agents and implants prepared from same |
| GB201314312D0 (en) * | 2013-08-09 | 2013-09-25 | Regentec Ltd | Composition and delivery system |
| CN103623415B (zh) * | 2013-12-04 | 2015-03-25 | 北京诺康达医药科技有限公司 | 一种用于生物多肽制剂的plga与乙醇的复合物 |
| EP3177319A1 (en) * | 2014-08-04 | 2017-06-14 | Janssen Sciences Ireland UC | Compacted solid dosage form |
| GB201702475D0 (en) * | 2017-02-15 | 2017-03-29 | Locate Therapeutics Ltd | Tissue scaffold and scaffold composition |
| EP3459527B1 (en) * | 2017-09-20 | 2022-11-23 | Tillotts Pharma Ag | Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0549629A (ja) * | 1991-08-23 | 1993-03-02 | Konica Corp | 医用放射線画像読影装置 |
| US5520923A (en) * | 1994-09-19 | 1996-05-28 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
| IT1304152B1 (it) * | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| CN100446809C (zh) | 2001-11-14 | 2008-12-31 | 阿尔扎有限公司 | 可注射的长效组合物 |
-
2003
- 2003-06-26 IT IT001302A patent/ITMI20031302A1/it unknown
-
2004
- 2004-06-24 DE DE602004014496T patent/DE602004014496D1/de not_active Expired - Lifetime
- 2004-06-24 US US10/562,707 patent/US8206621B2/en not_active Expired - Fee Related
- 2004-06-24 MX MXPA05013697A patent/MXPA05013697A/es active IP Right Grant
- 2004-06-24 BR BRPI0411759-0A patent/BRPI0411759A/pt not_active IP Right Cessation
- 2004-06-24 AT AT04741884T patent/ATE398447T1/de active
- 2004-06-24 JP JP2006516183A patent/JP2009513165A/ja active Pending
- 2004-06-24 CA CA2530117A patent/CA2530117C/en not_active Expired - Fee Related
- 2004-06-24 WO PCT/EP2004/051226 patent/WO2005000277A1/en not_active Ceased
- 2004-06-24 PL PL04741884T patent/PL1638534T3/pl unknown
- 2004-06-24 CN CNB2004800177773A patent/CN100509060C/zh not_active Expired - Fee Related
- 2004-06-24 KR KR1020057024514A patent/KR101143771B1/ko not_active Expired - Fee Related
- 2004-06-24 PT PT04741884T patent/PT1638534E/pt unknown
- 2004-06-24 AU AU2004251456A patent/AU2004251456B2/en not_active Ceased
- 2004-06-24 EP EP04741884A patent/EP1638534B1/en not_active Expired - Lifetime
- 2004-06-24 ES ES04741884T patent/ES2308195T3/es not_active Expired - Lifetime
-
2008
- 2008-09-17 CY CY20081101000T patent/CY1108346T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1638534E (pt) | 2008-09-29 |
| EP1638534B1 (en) | 2008-06-18 |
| MXPA05013697A (es) | 2006-05-17 |
| DE602004014496D1 (de) | 2008-07-31 |
| KR101143771B1 (ko) | 2012-05-11 |
| KR20060079146A (ko) | 2006-07-05 |
| WO2005000277A1 (en) | 2005-01-06 |
| AU2004251456A1 (en) | 2005-01-06 |
| AU2004251456B2 (en) | 2009-12-03 |
| US20060171987A1 (en) | 2006-08-03 |
| US8206621B2 (en) | 2012-06-26 |
| CY1108346T1 (el) | 2014-02-12 |
| EP1638534A1 (en) | 2006-03-29 |
| ITMI20031302A0 (it) | 2003-06-26 |
| CN1812770A (zh) | 2006-08-02 |
| JP2009513165A (ja) | 2009-04-02 |
| ES2308195T3 (es) | 2008-12-01 |
| PL1638534T3 (pl) | 2009-02-27 |
| ITMI20031302A1 (it) | 2004-12-27 |
| CA2530117A1 (en) | 2005-01-06 |
| CN100509060C (zh) | 2009-07-08 |
| BRPI0411759A (pt) | 2006-08-08 |
| HK1089954A1 (en) | 2006-12-15 |
| ATE398447T1 (de) | 2008-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2530117C (en) | Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a plga matrix | |
| JP3445283B2 (ja) | ヒアルロン酸の微細粒子中に封入された薬物の徐放性組成物 | |
| US5081156A (en) | Sustained-release preparation | |
| US4849141A (en) | Method for producing sustained release formulation | |
| US5385738A (en) | Sustained-release injection | |
| JPS61194034A (ja) | 経鼻投与用粉末状組成物 | |
| EP0140255B1 (en) | Sustained-release injections | |
| DE3486029T2 (de) | Ifn-praeparat mit verzoegerter abgabe fuer parentale verabreichung. | |
| PL200954B1 (pl) | Lipofilowe mikrocząsteczki zawierające lek proteinowy lub peptydowy i preparat zawierający te mikrocząsteczki | |
| TW457099B (en) | Sustained release composition of animal growth hormone and process for preparation thereof | |
| KR20210100986A (ko) | 고밀도 서방출성 미립구의 제조방법 | |
| US8987340B2 (en) | Sublimable sustained release delivery system and method of making same | |
| JPH10504531A (ja) | Ｈｇｈ含有医薬組成物 | |
| JPS60112713A (ja) | 有用な徐放性注射剤 | |
| HK1089954B (en) | Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a plga matrix | |
| KR100329336B1 (ko) | 히아루론산을 이용한 단백질 약물의 서방성 미세 입자 제형 | |
| JPH0372046B2 (enExample) | ||
| JPH09508118A (ja) | 水性持続放出性処方 | |
| JP2539245B2 (ja) | ポリ乳酸組成物 | |
| JPH05246879A (ja) | 長期徐放性製剤 | |
| HK1020885B (en) | Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20150625 |